CA-USERTESTING
26.7.2022 09:02:12 CEST | Business Wire | Press release
UserTesting (NYSE: USER), a leader in video-based human insight , today announced that UserTesting CEO Andy MacMillan will be joining host Nick Murray, Co-Director Startup Grind Scotland and Strategic Partnerships Manager, Metanomic, for a discussion focused on topics that include empathy in leadership, and what makes Edinburgh an ideal location as a European headquarters for technology companies. This event is taking place on Thursday, August 4, at UserTesting’s European headquarters in Edinburgh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005085/en/
Attendees also can hear what Scotland can learn from Silicon Valley’s mindset, the value of customer insights in helping to drive business decisions during challenging economic periods, and lessons learned from rapidly growing a SaaS company through an IPO.
Discussion Details:
- Date: Thursday, August 4, 2022
- Time: 6:00 p.m. to 9:00 p.m., BST
- Location: UserTesting EMEA Headquarters, 2nd Floor, 7 Exchange Crescent, Edinburgh, EH3 8AN
- Cost: 6 GBP public, Free for UserTesting team members (prior registration required)
-
Speakers:
- Andy MacMillan, CEO of UserTesting
- Nick Murray, Host and Co-Director Startup Grind Scotland
"Community gatherings with globally-proven industry experts are critical to developing Scotland's entrepreneurial ecosystem," said Nick Murray, Co-Director of Startup Grind Scotland. "Our first interview with Andy in Silicon Valley this April was a significant mindset shift for the 20 Scottish founders we took to the entrepreneurship mecca. With the Scottish Government announcing Scotland's Tech Scaler Hubs this month, now is the perfect time to look internationally to find best practices and learn from those who have been there before. This interview will broaden the horizons of what's possible for Scottish businesses through the eyes of someone who has had incredible success in scaling a SAAS business to a global entity."
“Selecting Edinburgh was the right choice for UserTesting’s European headquarters, and we are excited to be a part of this event, highlighting the value we have found in establishing offices here,” said Andy MacMillan, CEO of UserTesting. “UserTesting is proud to support Edinburgh’s, and Scotland’s, growing technology scene. There are great opportunities for companies in Scotland, due to the local education system, partnership opportunities with local government agencies, and the local talent, which is what global technology companies are looking for today.”
About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com
.
About Startup Grind Scotland
Startup Grind is the world's largest community of startups, founders, innovators, and creators based in 125+ countries with 600 chapters worldwide. Startup Grind Scotland is committed to supporting Scotland's vibrant entrepreneurial community, hosting fireside chats and panel conversations with some of Scotland's most influential and exciting business leaders. Past speakers include Mark Logan (Scotland's Chief Entrepreneur and ex-Skyscanner COO), Darina Garland (co-founder, Ooni) and Evelyn McDonald (CEO, Scottish EDGE).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005085/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom